ArticlePharmaceutical research2026
Effect of Oral Creatine Supplementation on Plasma, Central, and Peripheral Creatine Levels in Creatine Transporter Deficiency Mice.
Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeCreatine transporter deficiency (CRTD) is characterized by severe brain creatine depletion due to creatine transporter (CRT) dysfunction. Although oral creatine supplementation has been explored as a therapy, its effects under CRT-deficient conditions remain unclear. Here, we aimed to investigate the impact of oral creatine supplementation on creatine distribution in plasma, brain, and peripheral tissues using CRTD model mice.
methodsCreatine was orally administered for 30 days to creatine transporter knockout (Slc6a8
resultsOral creatine supplementation significantly increased plasma creatine in both CRT-KO and CRT-KI mice but failed to restore creatine levels in the brain. Conversely, creatine levels increased markedly in the liver and kidney. Urinary creatine and the creatine-to-creatinine ratio, a key diagnostic biomarker for CRTD, were substantially elevated, exceeding diagnostic thresholds even in WT mice.
conclusionsOral creatine increases systemic creatine but fails to restore brain creatine under CRT-deficient conditions, underscoring the crucial role of CRT-mediated blood-brain barrier (BBB) uptake and the need to restore creatine transport across the BBB to elevate brain creatine levels. Furthermore, creatine intake should be controlled for proper diagnostic biomarker interpretation.
Indexed as
Identifiers
42934368What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.